Nevada’s Vetoed Insulin Cost Transparency Bill Returns, as California Advances Several Pricing Measures Post author:Sam Post published:June 5, 2017 Post category:Drug Industry Daily Lawmakers in Nevada and California continue to target drugmakers in health care proposals. Source: Drug Industry Daily You Might Also Like FDA Updates 2003 MAPP on Requesting Exemptions From Environmental Assessment Requirements September 14, 2017 Agreement Cuts Common Canadian Generics Prices by Up to 40 Percent January 29, 2018 Gottlieb Nomination Moves on to Full Senate April 27, 2017
FDA Updates 2003 MAPP on Requesting Exemptions From Environmental Assessment Requirements September 14, 2017